Estados Unidos · Plataformas y datos · Morningstar

Rakuten Medical Presents Long-Term Follow-up Results of ASP-1929 Photoimmunotherapy in Combination with Pembrolizumab for R/M HNSCC at ESMO 2026

Publicado por Morningstar · Estados Unidos hace 8 h

The ASP-1929-181 study enrolled 19 patients with r/m HNSCC, and the long-term follow-up analysis included 17 efficacy-evaluable patients. Median overall survival (OS) was 28.2…

Leer el artículo completo en Morningstar Inicie sesión para guardar

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.morningstar.com)

Rakuten Medical Presents Long-Term Follow-up Results of ASP-1929 Photoimmunotherapy in Combination with Pembrolizumab for R/M HNSCC at ESMO 2026

También te puede interesar

JPMorgan Chase & Co. $JPM Stock Sold by Grandview Asset Management LLC

France business activity deteriorates in October, missing consensus

My father-in-law, 81, sold his $75,000 home to pay his daughter’s $50,000 debt. How can I keep him from becoming destitute?

Not Bitcoin. Not Ethereum. This Once-Popular Cryptocurrency Could Be the Biggest Winner of 2027.

Why is Crest Nicholson stock falling today?

Stocktwits AI Roundup: Meta’s Capex, Lam’s Supply Warning Hit Tech Stocks As Netflix Disappoints

Rakuten Medical Presents Long-Term Follow-up Results of ASP-1929 Photoimmunotherapy in Combination with Pembrolizumab for R/M HNSCC at ESMO 2026

Compartir

También te puede interesar

JPMorgan Chase & Co. $JPM Stock Sold by Grandview Asset Management LLC

France business activity deteriorates in October, missing consensus

My father-in-law, 81, sold his $75,000 home to pay his daughter’s $50,000 debt. How can I keep him from becoming destitute?

Not Bitcoin. Not Ethereum. This Once-Popular Cryptocurrency Could Be the Biggest Winner of 2027.

Why is Crest Nicholson stock falling today?

Stocktwits AI Roundup: Meta’s Capex, Lam’s Supply Warning Hit Tech Stocks As Netflix Disappoints